Loïck Vidot
Institut de Recherches Internationales Servier (France) · 17 works · 601 citations · h-index 5
Top works
- Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
- SO-18 Reinforcing clinical outcomes with patient-reported QoL outcomes in patients with mCRC receiving FTD/TPI: Pooled analysis of PRECONNECT and TALLISUR studies
- Effect of trifluridine/tipiracil in patients treated in RECOURSE by prognostic factors at baseline: an exploratory analysis
- Safety, efficacy and patient-reported outcomes with trifluridine/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study
- SO-18 Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: Final results according to duration of treatment from the phase IIIb, international, open-label, early-access PRECONNECT study
- Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: final results from the phase IIIb single-arm PRECONNECT study by duration of therapy
- Exploratory analysis of the effect of FTD/TPI in patients treated in RECOURSE by prognostic factors.
- Health-related quality of life in the early-access phase IIIb study of trifluridine/tipiracil in pretreated metastatic colorectal cancer (mCRC): Results from PRECONNECT study.
- Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: PRECONNECT Turkey
- Futility Interim Analysis Based on Probability of Success Using a Surrogate Endpoint
- Correction: STK11 and KEAP1 mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort
- Exploratory analysis of the effect of FTD/TPI in mCRC patients treated in RECOURSE by different prognostic factors: impact on ECOG PS
- Clinical and quality of life outcomes with trifluridine/tipiracil: PRECONNECT and TALLISUR studies
- Brazilian cohort results of the PRECONNECT study: safety and efficacy of trifluridine/tipiracil in metastatic colorectal cancer
- PCN49 INDIRECT COMPARISON OF HRQOL DATA FOR PATIENTS WITH TREATMENT-REFRACTORY METASTATIC COLORECTAL CANCER TREATED WITH TRIFLURIDINE & TIPIRACIL (PRECONNECT TRIAL) COMPARED WITH BSC & REGORAFENIB (CORRECT TRIAL)